Pathological and endocrinological effect of anabolic-androgenic steroid in male rats

有许多运动员使用提高成绩的药物，特别是合成代谢雄激素类固醇（AAS）。然而，关于AAS滥用者可能发生的内分泌和病理变化的报道很少。在本研究中，我们报告了AAS治疗大鼠的内分泌检查结果和身体变化。我们分开。7周龄雄性Wister大鼠37只，分为3组：A组给予癸酸诺龙、醋酸美替诺龙、顺莫stanolone治疗；B组采用癸酸诺龙加生理盐水治疗，C组采用生理盐水治疗。大鼠分别皮下注射药物或对照组，每周一次，连续注射6周。停止治疗4周，再继续治疗6周。第二个疗程后，处死大鼠。A组血清睾酮水平显著高于c组。A组血清双氢睾酮水平显著高于B组和c组。A组和B组血清雌二醇-1 - 7 - 13水平显著高于c组。病理检查显示心脏、睾丸和肾上腺损伤严重。大鼠在接受AAS治疗的同时进行运动训练，如跳跃训练等，其副作用与单独接受AAS治疗的大鼠相似，即红细胞增加，心脏肥大，GOT和LDH升高。然而，这些副作用在运动的大鼠中更为严重。这些发现表明，使用AAS有很高的风险。

There are many athletes who use performance-enhancing drugs, especially anabolic androgenic steroids (AAS).However there are few reports about the endocrinological and pathological changes that may occur in AAS abusers.In this study, we report the results of endocrinological examinations and physical changes in rats treated with AAS. We separated. 37 male Wister rats (7 weeks old) into 3 groups: group A was treated with nandrolone decanoate, metenolone acetate, and dromostanolone; group B was treated with nandrolone decanoate and saline, and group C was treated with saline. Rats received subcutaneous injections of the medications or the control vehicle once a week for 6 weeks. Treatment was stopped for 4 weeks, then resumed for another 6 weeks.Following the second course of treatment, rats were sacrificed. Serum testosterone levels in group A was significantly higher than in group C. Serum dihydrotestosterone levels in group A were significantly higher than in both groups B and C. Serum estradiol-1 7 13 levels in groups A and B were significantly higher than in group C. Pathological evaluation revealed severe damage in heart, testis, and adrenal gland.Rats that underwent exercise training, such as Jump training etc. in addition to AAS treatment, had similar side effects as those observed in rats treated with AAS alone, i.e., an increase in erythrocytes, hypertrophy of the heart, and a rise of GOT and LDH. However, these side effects were more severe in the exercised rats.These findings indicate that there is a high degree of risk associated with the use of AAS.